Skip to main content
ASTAL LABORATORIES LIMITED logo

ASTAL LABORATORIES LIMITED — Investor Relations & Filings

Ticker · 512600 ISIN · INE307N01014 LEI · 8945004HO2WCBQ0CJ976 BSE.NS Manufacturing
Open in API
Filings indexed 442 across all filing types
Latest filing 2025-10-09 Capital/Financing Update
Country IN India
Listing BSE.NS 512600

About ASTAL LABORATORIES LIMITED

https://miel.co.in/

Astal Laboratories Limited is a pharmaceutical organization engaged in the development, manufacturing, and marketing of a diverse range of pharmaceutical formulations. The company's product portfolio encompasses various dosage forms, including tablets, capsules, liquid orals, and topical preparations. It operates across several therapeutic categories, such as anti-infectives, analgesics, and gastrointestinal treatments. Astal Laboratories prioritizes quality control and adheres to established manufacturing standards to ensure the safety and efficacy of its products. The company focuses on providing accessible healthcare solutions through a robust distribution network and a commitment to research-driven formulation development.

Recent filings

Filing Released Lang Actions
Submission of outcome of Board meeting.
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement of the outcome of a Board Meeting of Astal Laboratories Limited, dated October 9, 2025. It includes approval of a Share Purchase Agreement, increase in authorized share capital, and a preferential issue of shares as consideration for acquisition. The document contains detailed disclosures as required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, including annexures with specifics about the acquisition target, share capital changes, and issuance details. The content focuses on corporate actions related to capital structure changes and acquisition, with no financial statements or earnings data presented. The document is not a full financial report but an update on capital and financing activities, including share issuance and acquisition approvals. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length (15,000 characters) and detailed disclosures support a high confidence in this classification.
2025-10-09 English
Astal Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/10/2025 ,inter alia, to consider and approve 1) To increase authorised ....
Regulatory Filings Classification · 95% confidence The document is an intimation of a Board Meeting scheduled for October 9, 2025, to consider matters including increasing authorized share capital, issuance of equity shares/warrants, acquisition decisions, and approval of an Extraordinary General Meeting notice. It is addressed to the stock exchange under SEBI Listing Regulations, specifically Regulation 29, which pertains to disclosure of Board Meeting information. The document does not contain financial statements or detailed financial data but is a formal announcement of an upcoming Board Meeting and its agenda. The document length is 4467 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement about a Board Meeting and not a full management or financial report, nor a direct announcement of a capital change or share issue yet.
2025-10-03 English
Submission of intimation of trading window closure.
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to the stock exchange (BSE Limited) informing about the closure of the trading window for insiders due to upcoming unaudited financial results for the quarter ended 30th September 2025. It references SEBI (Prohibition of Insider Trading) Regulations, 2015, and specifies the trading window closure period but does not contain any financial data or results itself. The document is short (1999 characters) and serves as an announcement related to compliance and insider trading restrictions ahead of financial results disclosure. It is not the financial report itself, nor a transcript, audit report, or other detailed filing. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for such compliance and regulatory announcements that do not fit other specific categories.
2025-09-30 English
Submission of voting Results.
Regulatory Filings
2025-09-13 English
Submission of voting Results and Scrutinizer''s Report.
Regulatory Filings
2025-09-13 English
Submission of the outcome of 32nd Annual General meeting.
Regulatory Filings
2025-09-12 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.